Gyre Therapeutics, Inc. Excess Tax Benefit from Share-based Compensation, Operating Activities
Gyre Therapeutics, Inc. (GYRE) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $0 for the 9-month period ending 2011-09-30, per its 10-Q filed 2011-11-03.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2013-03-15
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, operating activities for the quarter ending 2011-09-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, operating activities for the quarter ending 2010-12-31 was $1.23M.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, operating activities for the quarter ending 2010-09-30 was $160.00K.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, operating activities for fiscal 2010 was $3.50M, a 8443.90% increase from fiscal 2009.
- Gyre Therapeutics, Inc. excess tax benefit from share-based compensation, operating activities for fiscal 2009 was $41.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month |
|---|---|---|---|---|
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $0.00 10-Q · filed 2011-11-03 | ||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-09 | |||
| 2010-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $1.39M derived: sum of 2 quarters · filed 2013-03-15 | $3.50M 10-K · filed 2013-03-15 | |
| 2010-09-30 | $160.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $2.28M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $2.12M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $41.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |